JANUVIA (Sitagliptin phosphate) is a medication used to treat type 2 diabetes mellitus. It should be as an adjunct to diet and exercise. JANUVIA should not be prescribed for type 1 diabetes mellitus or the treatment or diabetic ketoacidosis.
JANUVIA works by inhibiting the enzyme DPP-4 in the gastrointestinal tract. DPP-4 normally shuts off incretin hormones, and incretin hormones are responsible for promoting the digestion process and increasing the release of insulin. By blocking DPP-4, JANUVIA increases the activity of incretin hormones, causing a downstream increase in insulin. The net effect is to lower blood sugar.
Combined with diet and exercise, JANUVIA has been shown to decrease hemoglobin A1C, fasting plasma glucose (FPG), and 2-hour postprandial glucose (PPG).
Take JANUVIA 100 mg once daily with or without food.
The dose may be reduced to 25-50 mg once daily in patients with kidney problems.
The active ingredient in JANUVIA is sitagliptin.
After it’s market release, there have been reports of pancreatitis. Speak with your doctor if you have a personal or family history of pancreatitis.
During JANUVIA therapy, heart function should be monitored for patients at risk of heart failure. It should be used with caution or discontinued in those with active heart failure.
Patients with renal impairment or renal failure should use caution when taking JANUVIA.
JANUVIA has been known to cause rare and serious skin conditions. If you notice a skin reaction while taking JANUVIA, stop taking it and let your doctor know.
Speak with your doctor for a full list of warnings and precautions.
The most common side effects of JANUVIA are:
- Upper respiratory infection